Call it a symbiotic relationship or a shotgun wedding! Big pharma is the object of desire by the venture capital community, and the importance of their relationship to biotech community is huge. Pipeline gaps and patent expirations continue to create uncertainty for Pharma. The absence of an IPO window for private biotechs compels many to consider partnering early or acquisition. Even in a challenging economic environment, Venture Capitalist continue to raise money, but are reluctant to put it to work without a path to liquidity and a reasonable return. Join the brides and grooms in Big Pharma and Venture Capital to see if this marriage is forever or just a summer romance.

• Educate the biotech community about the impact which big pharma/venture capital has on their ability to partner and raise capital
• Identify the key player in the pharma and venture capital community with whom to network and consult on specifi c opportunities
• Share your views and situation in an interactive Q&A to generate useful information from thought leaders who are experts on this business trend